 This is a multicentric, non-inferiority, randomized controlled trial aiming at assessing the maternal and infant safety of a single daily fixed-dose combination of TDFFTCEFV Atripla, compared to the association of LPVr Kaletra or Aluvia and 3TCZDV Combivir given to African women in Cote dIvoire an in Zambia to prevent MTCT overall in breastfeeding population. 